The purpose of the Vector Production Core (Core B) is to develop and provide gene transfer reagents to members of the proposed Program efficiently and in a cost-effective manner. The research-grade vector development/production laboratory has been well established and centralized core component of the UCSD Gene Therapy Program and has demonstrated the benefit of such a core facility to the current program project as well as UCSD and other investigators through many venues. The Core laboratory has great expertise in the development and efficient preparation of a variety of high quality research-grade gene transfer vectors, including: adenovirus, multiple serotypes of adeno-associated virus (AAV), lentivirus, retrovirus (ecotropic, amphotropic, and VSV-G pseudotyped), VSV-G virosomes and plasmids. Since its inception in 1995, the Core has accommodated more than 780 requests, many of which have been development/preparation of multiple viral vectors. Technological innovation has also been an important function of the Core laboratory and it has made significant innovations to viral vectors, including improvement in vector production and purification procedures, development of double-strand DNA genome AAV vectors (scAAVs), tetracycline-inducible vectors, tissue-specific and tet-regulated vectors for shRNA/microRNA, and multiple gene expression from a single vector. Core B will work closely with project members, continue technological innovations and quickly incorporate new designs into the service function to provide the most efficient forms of gene transfer vectors to the proposed Program Project.
Every project within the proposed program involves intensive use of viral vectors for gene transfer and will require the expertise of the Core B. Core B will provide to the program participants with the most efficient and innovated form of gene transfer reagents and related services in a centralized manner. The resources are essential to the timely accomplishment of the goal of this program project.
|Pandey, Amit K; Penny, William F; Bhargava, Valmik et al. (2016) Clinical Evaluation of Heart Failure: Agreement among Tests. PLoS One 11:e0161536|
|Gao, Mei Hua; Giamouridis, Dimosthenis; Lai, N Chin et al. (2016) One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. JCI Insight 1:e88322|
|Schilling, Jan M; Horikawa, Yousuke T; Zemljic-Harpf, Alice E et al. (2016) Electrophysiology and metabolism of caveolin-3-overexpressing mice. Basic Res Cardiol 111:28|
|Cividini, Federico; Scott, Brian T; Dai, Anzhi et al. (2016) O-GlcNAcylation of 8-Oxoguanine DNA Glycosylase (Ogg1) Impairs Oxidative Mitochondrial DNA Lesion Repair in Diabetic Hearts. J Biol Chem 291:26515-26528|
|See Hoe, Louise E; Schilling, Jan M; Busija, Anna R et al. (2016) Chronic Î²1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium. Eur J Pharmacol 789:1-7|
|Tran, Chinh; Stary, Creed M; Schilling, Jan M et al. (2015) Role of caveolin-3 in lymphocyte activation. Life Sci 121:35-9|
|Lai, N Chin; Gao, Mei Hua; Giamouridis, Dimosthenis et al. (2015) Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice. Hum Gene Ther 26:347-56|
|Schilling, Jan M; Roth, David M; Patel, Hemal H (2015) Caveolins in cardioprotection - translatability and mechanisms. Br J Pharmacol 172:2114-25|
|Sun, Junhui; Nguyen, Tiffany; Aponte, Angel M et al. (2015) Ischaemic preconditioning preferentially increases protein S-nitrosylation in subsarcolemmal mitochondria. Cardiovasc Res 106:227-36|
|Markandeya, Yogananda S; Phelan, Laura J; Woon, Marites T et al. (2015) Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase CÎ± in Cardiomyocytes. J Biol Chem 290:22085-100|
Showing the most recent 10 out of 75 publications